ArticleFEBS open bio2016
MicroRNA-520c enhances cell proliferation, migration, and invasion by suppressing IRF2 in gastric cancer.
Article in FEBS open bio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Retraction: LncRNA CHRFinduced miR-489 loss promotes metastasis of colorectal cancer via TWIST1/EMT signaling pathway.Oncotarget · 2026Article
- MicroRNAs in cancer metastasis: biological and therapeutic implications.Expert reviews in molecular medicine · 2023Review
- IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer.Journal of translational medicine · 2022Article
- IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis.Molecular medicine reports · 2022Article
- MicroRNAs are involved in the development and progression of gastric cancer.Acta pharmacologica Sinica · 2021Review
- MicroRNA-520c-3p suppresses vascular endothelium dysfunction by targeting RELA and regulating the AKT and NF-κB signaling pathways.Journal of physiology and biochemistry · 2021Article
- MicroRNAs and Metastasis.Cancers · 2019Review
- IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.Biological research · 2019Article
- miR‑3666 suppresses cellular proliferation and invasion in colorectal cancer by targeting SATB2.Molecular medicine reports · 2018Article
- MiR-4463 inhibits the migration of human aortic smooth muscle cells by AMOT.Bioscience reports · 2018Article
- GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis.The Journal of biological chemistry · 2018Article
- Prognostic value of microRNAs in gastric cancer: a meta-analysis.Oncotarget · 2017Article
Corrections and comments
- Retraction · 2022-11-15Concerns/Issues about Data · Duplication of/in Image · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/BBCD2B15408DC4D570541F2161DD27
- Retracted
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of microRNA (miRNA) is actively involved in the development and progression of gastric cancer (GC). MiR-520c was previously found to be overexpressed in GC specimens and cells. However, the clinical significance of miR-520c and its biological function in GC remain largely unknown. Here, we found that miR-520c expression in GC tissues was significantly increased compared to normal adjacent gastric tissues. Its increased level was prominently correlated with poor clinical parameters and prognosis of GC patients. Accordingly, the expression of miR-520c was obviously elevated in GC cell lines as compared with gastric epithelial cells. Overexpression of miR-520c in N-87 cells significantly increased the proliferative ability, migration, and invasion of cancer cells, while miR-520c silencing suppressed MKN-45 cell proliferation, migration, and invasion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.